person · Reporting owner
TOMSICEK MICHAEL JOHN
Disclosed activity across 4 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABIOMED INCABMD · Entity 121309 | Vice President, CFO | July 15, 2017 | July 18, 2017 |
| Acrivon Therapeutics, Inc.ACRV · Entity 573 | Director | June 17, 2026 | June 22, 2026 |
| CRISPR Therapeutics AGCRSP · Entity 3852 | Chief Financial Officer | August 06, 2021 | August 11, 2021 |
| Milestone Pharmaceuticals Inc.MIST · Entity 6561 | Director | June 10, 2026 | June 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABIOMED INC
Report date July 15, 2017 · Filed July 18, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $.01 par valueSEC Table I · non-derivative | Direct | 27,081 |
Reported balance
After 2017-07-15 transaction · row 1
1 source rowRow 1 · 2017-07-15 · Tax withholding · Disposed 3,925 · Balance 27,081 F5: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with vesting of awards of restricted stock units. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $67.55 · Expires 2025-07-15 | Direct | 25,000 |
Reported balance
Holding disclosure · report date 2017-07-15 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 25,000 F1: Grant to reporting person of option to buy the number of shares of common stock set forth on Table II, Column 7, under the Abiomed, Inc. 2008 Stock Incentive Plan. F2: These options become exercisable in annual 25% increments, commencing on the date shown in Table II, Column 6. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $99.62 · Expires 2026-05-24 | Direct | 5,000 |
Reported balance
Holding disclosure · report date 2017-07-15 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 5,000 F3: Grant to reporting person of option to buy the number of shares of Common Stock set forth in Table II, Column 7, under the ABIOMED, Inc. 2015 Omnibus Incentive Plan. F4: These options become exercisable in annual 33-1/3% increments, commencing on the date shown in Table II, Column 6. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $134.51 · Expires 2027-05-15 | Direct | 6,000 |
Reported balance
Holding disclosure · report date 2017-07-15 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 6,000 F3: Grant to reporting person of option to buy the number of shares of Common Stock set forth in Table II, Column 7, under the ABIOMED, Inc. 2015 Omnibus Incentive Plan. F4: These options become exercisable in annual 33-1/3% increments, commencing on the date shown in Table II, Column 6. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant to reporting person of option to buy the number of shares of common stock set forth on Table II, Column 7, under the Abiomed, Inc. 2008 Stock Incentive Plan.
F2: These options become exercisable in annual 25% increments, commencing on the date shown in Table II, Column 6.
F3: Grant to reporting person of option to buy the number of shares of Common Stock set forth in Table II, Column 7, under the ABIOMED, Inc. 2015 Omnibus Incentive Plan.
F4: These options become exercisable in annual 33-1/3% increments, commencing on the date shown in Table II, Column 6.
F5: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with vesting of awards of restricted stock units.
Acrivon Therapeutics, Inc.
Report date June 17, 2026 · Filed June 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.52 · Expires 2036-06-16 | Direct | 20,275 |
Reported balance
After 2026-06-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-17 · Grant · Acquired 20,275 · Balance 20,275 F1: The shares subject to the option shall vest on the date immediately preceding the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option shall vest on the date immediately preceding the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through the applicable vesting date.
CRISPR Therapeutics AG
Report date August 06, 2021 · Filed August 11, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 1,891 |
Ending reported balance
After 2021-08-06 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2021-08-06 · Exercise / conversion · Acquired 25,000 · Balance 26,891 Row 2 · 2021-08-06 · Sale · Disposed 19,011 · Balance 7,880 F1: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $138.00 to $138.97, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Row 3 · 2021-08-06 · Sale · Disposed 5,989 · Balance 1,891 F1: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $139.06 to $139.69, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.75 · Expires 2027-11-21 | Direct | 131,000 |
Reported balance
After 2021-03-11 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-03-11 · Exercise / conversion · Disposed 25,000 · Balance 131,000 F4: This option was granted on November 13, 2017, 25% of the shares vested on November 13, 2018 and the remaining shares vest in 36 equal monthly installments on the first day of each succeeding calendar month. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $138.00 to $138.97, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $139.06 to $139.69, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
F4: This option was granted on November 13, 2017, 25% of the shares vested on November 13, 2018 and the remaining shares vest in 36 equal monthly installments on the first day of each succeeding calendar month.
Milestone Pharmaceuticals Inc.
Report date June 10, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.22 · Expires 2036-06-10 | Direct | 77,000 |
Reported balance
After 2026-06-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-10 · Grant · Acquired 77,000 · Balance 77,000 F1: This option will vest in twelve (12) equal monthly installments, beginning on July 10, 2026, provided that the option will in any case be fully vested on the date of next annual meeting of the stockholders of the Issuer, subject to the Reporting Person continuing to provide service through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option will vest in twelve (12) equal monthly installments, beginning on July 10, 2026, provided that the option will in any case be fully vested on the date of next annual meeting of the stockholders of the Issuer, subject to the Reporting Person continuing to provide service through each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 17, 2026 Filed Jun 22, 2026 20:14 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | GrantStock Option (Right to Buy) · Derivative | 20,275 | $0.00 Strike: $1.52 | $0.00 |
DisclosureSEC source: 0000905148-26-003042 · form4.xml · derivative · entry 1 TOMSICEK MICHAEL JOHN · CIK 0001570392 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,275 Underlying: Common Stock · 20,275 shares Expires 2036-06-16 F1 · derivative.exercise_date: The shares subject to the option shall vest on the date immediately preceding the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through the applicable vesting date. Read SEC document |
| June 10, 2026 Filed Jun 12, 2026 20:15 UTC | Milestone Pharmaceuticals Inc. MIST · Entity 6561 | GrantStock Option (right to buy) · Derivative | 77,000 | $0.00 Strike: $1.22 | $0.00 |
DisclosureSEC source: 0001570392-26-000003 · form4-06122026_040614.xml · derivative · entry 1 TOMSICEK MICHAEL JOHN · CIK 0001570392 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,000 Underlying: Common Stock · 77,000 shares Expires 2036-06-10 F1 · derivative.exercise_date: This option will vest in twelve (12) equal monthly installments, beginning on July 10, 2026, provided that the option will in any case be fully vested on the date of next annual meeting of the stockholders of the Issuer, subject to the Reporting Person continuing to provide service through each such vesting date. Read SEC document |
| May 18, 2026 Filed May 20, 2026 20:36 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | GrantCommon Stock | 9,366 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-26-002563 · form4.xml · nonDerivative · entry 1 TOMSICEK MICHAEL JOHN · CIK 0001570392 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,366 F1 · kind: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. These RSUs shall vest in full on May 18, 2027, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| June 13, 2025 Filed Jun 17, 2025 21:57 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | GrantStock Option (Right to Buy) · Derivative | 20,275 | $0.00 Strike: $1.20 | $0.00 |
DisclosureSEC source: 0000905148-25-002174 · form4.xml · derivative · entry 1 TOMSICEK MICHAEL JOHN · CIK 0001570392 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,275 Underlying: Common Stock · 20,275 shares Expires 2035-06-12 F1 · derivative.exercise_date: The shares subject to the option shall vest on the date immediately preceding the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through the applicable vesting date. Read SEC document |
| June 10, 2025 Filed Jun 12, 2025 20:19 UTC | Milestone Pharmaceuticals Inc. MIST · Entity 6561 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $1.75 | $0.00 |
DisclosureSEC source: 0001415889-25-016934 · form4-06122025_040614.xml · derivative · entry 1 TOMSICEK MICHAEL JOHN · CIK 0001570392 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2035-06-10 F1 · derivative.exercise_date: This option will vest in twelve (12) equal monthly installments, beginning on July 10, 2025, provided that the option will in any case be fully vested on the date of next annual meeting of the stockholders of the Issuer, subject to the Reporting Person continuing to provide service through each such vesting date. Read SEC document |
| August 28, 2024 Filed Aug 29, 2024 20:15 UTC | Milestone Pharmaceuticals Inc. MIST · Entity 6561 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $1.45 | $0.00 |
DisclosureSEC source: 0001415889-24-022535 · form4-08292024_040808.xml · derivative · entry 1 TOMSICEK MICHAEL JOHN · CIK 0001570392 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Shares · 40,000 shares Expires 2034-08-28 F1 · derivative.exercise_date: This option will vest in twelve (12) equal monthly installments, beginning on September 28, 2024, provided that the option will in any case be fully vested on the date of next annual meeting of the stockholders of the Issuer, subject to the Reporting Person continuing to provide service through each such vesting date. Read SEC document |
| June 20, 2024 Filed Jun 24, 2024 21:28 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | GrantStock Option (Right to Buy) · Derivative | 20,275 | $0.00 Strike: $6.52 | $0.00 |
DisclosureSEC source: 0000905148-24-001777 · form4.xml · derivative · entry 1 TOMSICEK MICHAEL JOHN · CIK 0001570392 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,275 Underlying: Common Stock · 20,275 shares Expires 2034-06-19 F1 · derivative.exercise_date: The shares subject to the option shall vest on the date immediately preceding the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 20:22 UTC | Milestone Pharmaceuticals Inc. MIST · Entity 6561 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $3.86 | $0.00 |
DisclosureSEC source: 0001209191-23-035843 · doc4.xml · derivative · entry 1 TOMSICEK MICHAEL JOHN · CIK 0001570392 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Shares · 30,000 shares Expires 2033-06-07 F1 · derivative.exercise_date: This option will vest in twelve (12) equal monthly installments, beginning on July 7, 2023, provided that the option will in any case be fully vested on the date of next annual meeting of the stockholders of the Issuer, subject to the Reporting Person continuing to provide service through each such vesting date. Read SEC document |
| November 14, 2022 Filed Nov 17, 2022 00:25 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | GrantStock Option (Right to Buy) · Derivative | 35,235 | $0.00 Strike: $12.50 | $0.00 |
DisclosureSEC source: 0001209191-22-057401 · doc4.xml · derivative · entry 1 TOMSICEK MICHAEL JOHN · CIK 0001570392 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,235 Underlying: Common Stock · 35,235 shares Expires 2032-11-13 F1 · derivative.exercise_date: The shares subject to the option shall vest in 36 equal monthly installments beginning on October 12, 2022 ("Vesting Commencement Date"), such that all shares are fully vested on the third anniversary of the Vesting Commencement Date, in each case subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| October 19, 2022 Filed Oct 21, 2022 23:01 UTC | Milestone Pharmaceuticals Inc. MIST · Entity 6561 | PurchaseCommon Shares | 15,000 | $5.32 | $79,800.00 |
DisclosureSEC source: 0001209191-22-054325 · doc4.xml · nonDerivative · entry 1 TOMSICEK MICHAEL JOHN · CIK 0001570392 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions within a one dollar range. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| July 05, 2022 Filed Aug 11, 2022 22:03 UTC | Milestone Pharmaceuticals Inc. MIST · Entity 6561 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $6.07 | $0.00 |
DisclosureSEC source: 0001209191-22-045474 · doc4.xml · derivative · entry 1 TOMSICEK MICHAEL JOHN · CIK 0001570392 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Shares · 30,000 shares Expires 2032-07-05 F1 · derivative.exercise_date: This option will vest in twelve (12) equal monthly installments, beginning on August 5, 2022, provided that the option will in any case be fully vested on the date of next annual meeting of the stockholders of the Issuer, subject to the Reporting Person continuing to provide service through each such vesting date. Read SEC document |
| August 06, 2021 Filed Aug 11, 2021 00:00 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 5,989 | $139.46 | $835,225.94 |
DisclosureSEC source: 0001209191-21-050719 · doc4.xml · nonDerivative · entry 3 TOMSICEK MICHAEL JOHN · CIK 0001570392 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,891 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $139.06 to $139.69, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 06, 2021 Filed Aug 11, 2021 00:00 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 19,011 | $138.22 | $2,627,700.42 |
DisclosureSEC source: 0001209191-21-050719 · doc4.xml · nonDerivative · entry 2 TOMSICEK MICHAEL JOHN · CIK 0001570392 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,880 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $138.00 to $138.97, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 06, 2021 Filed Aug 11, 2021 00:00 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 25,000 | $17.75 | $443,750.00 |
DisclosureSEC source: 0001209191-21-050719 · doc4.xml · nonDerivative · entry 1 TOMSICEK MICHAEL JOHN · CIK 0001570392 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,891 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 14, 2021 Filed Jul 29, 2021 21:39 UTC | Milestone Pharmaceuticals Inc. MIST · Entity 6561 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $5.54 | $0.00 |
DisclosureSEC source: 0001209191-21-048573 · doc4.xml · derivative · entry 1 TOMSICEK MICHAEL JOHN · CIK 0001570392 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Shares · 30,000 shares Expires 2031-06-14 F1 · derivative.exercise_date: This option will vest in twelve (12) equal monthly installments, beginning on July 14, 2021, provided that the option will in any case be fully vested on the date of next annual meeting of the stockholders of the Issuer, subject to the Reporting Person continuing to provide service through each such vesting date. Read SEC document |
| March 11, 2021 Filed Mar 12, 2021 22:50 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantRestricted Stock Units · Derivative | 9,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-020263 · doc4.xml · derivative · entry 4 TOMSICEK MICHAEL JOHN · CIK 0001570392 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Shares · 9,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F5 · derivative.exercise_date: This restricted stock unit award was granted on March 11, 2021 with respect to 9,000 Common Shares, with (i) one quarter of the shares vesting on March 11, 2022, (ii) one quarter of the shares vesting on March 11, 2023, (iii) one quarter of the shares vesting on March 11, 2024, and (iv) one quarter of the shares vesting on March 11, 2025. F5 · derivative.expiration_date: This restricted stock unit award was granted on March 11, 2021 with respect to 9,000 Common Shares, with (i) one quarter of the shares vesting on March 11, 2022, (ii) one quarter of the shares vesting on March 11, 2023, (iii) one quarter of the shares vesting on March 11, 2024, and (iv) one quarter of the shares vesting on March 11, 2025. Read SEC document |
| March 11, 2021 Filed Mar 12, 2021 22:50 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantStock Option (Right to Buy) · Derivative | 25,360 | $0.00 Strike: $133.88 | $0.00 |
DisclosureSEC source: 0001209191-21-020263 · doc4.xml · derivative · entry 3 TOMSICEK MICHAEL JOHN · CIK 0001570392 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,360 Underlying: Common Shares · 25,360 shares Expires 2031-03-11 F4 · derivative.exercise_date: This option was granted on March 11, 2021 with respect to 25,360 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of April 11, 2021. Read SEC document |
| March 11, 2021 Filed Aug 11, 2021 00:00 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $17.75 | $0.00 |
DisclosureSEC source: 0001209191-21-050719 · doc4.xml · derivative · entry 4 TOMSICEK MICHAEL JOHN · CIK 0001570392 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,000 Underlying: Common Shares · 25,000 shares Expires 2027-11-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option was granted on November 13, 2017, 25% of the shares vested on November 13, 2018 and the remaining shares vest in 36 equal monthly installments on the first day of each succeeding calendar month. Read SEC document |
| March 10, 2021 Filed Mar 12, 2021 22:50 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Tax withholdingCommon Shares | 1,352 | $124.15 | $167,850.80 |
DisclosureSEC source: 0001209191-21-020263 · doc4.xml · nonDerivative · entry 2 TOMSICEK MICHAEL JOHN · CIK 0001570392 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,891 F3 · shares: Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 10, 2021 Filed Mar 12, 2021 22:50 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 2,833 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-020263 · doc4.xml · nonDerivative · entry 1 TOMSICEK MICHAEL JOHN · CIK 0001570392 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,243 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This restricted stock unit award was granted on March 10, 2020 with respect to 8,500 Common Shares, with (i) one third of the shares vesting on March 10, 2021, (ii) one third of the shares shares vesting on March 10, 2022, and (iii) one third of the shares vesting on March 10, 2023. F2 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. Read SEC document |
| October 05, 2020 Filed Oct 6, 2020 21:48 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantStock Option (Right to Buy) · Derivative | 11,666 | $0.00 Strike: $86.75 | $0.00 |
DisclosureSEC source: 0001209191-20-054070 · doc4.xml · derivative · entry 1 TOMSICEK MICHAEL JOHN · CIK 0001570392 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,666 Underlying: Common Shares · 11,666 shares Expires 2030-10-05 F1 · derivative.exercise_date: This option was granted on October 5, 2020 with respect to 11,666 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of November 5, 2020. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 20:46 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,000 | $0.00 Strike: $17.75 | $0.00 |
DisclosureSEC source: 0001209191-20-049430 · doc4.xml · derivative · entry 5 TOMSICEK MICHAEL JOHN · CIK 0001570392 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,000 Underlying: Common Shares · 12,000 shares Expires 2027-11-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This option was granted on November 13, 2017, 25% of the shares vested on November 13, 2018 and the remaining shares vest in 36 equal monthly installments on the first day of each succeeding calendar month. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 20:46 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 2,800 | $93.18 | $260,904.00 |
DisclosureSEC source: 0001209191-20-049430 · doc4.xml · nonDerivative · entry 4 TOMSICEK MICHAEL JOHN · CIK 0001570392 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 410 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.82 to $93.74, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 20:46 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 6,400 | $92.23 | $590,272.00 |
DisclosureSEC source: 0001209191-20-049430 · doc4.xml · nonDerivative · entry 3 TOMSICEK MICHAEL JOHN · CIK 0001570392 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,210 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.80 to $92.72, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 20:46 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 2,800 | $91.39 | $255,892.00 |
DisclosureSEC source: 0001209191-20-049430 · doc4.xml · nonDerivative · entry 2 TOMSICEK MICHAEL JOHN · CIK 0001570392 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,610 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.78 to $91.76, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 20:46 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 12,000 | $17.75 | $213,000.00 |
DisclosureSEC source: 0001209191-20-049430 · doc4.xml · nonDerivative · entry 1 TOMSICEK MICHAEL JOHN · CIK 0001570392 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,410 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 20:20 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 5,448 | $87.33 | $475,790.18 |
DisclosureSEC source: 0001209191-20-045100 · doc4.xml · nonDerivative · entry 3 TOMSICEK MICHAEL JOHN · CIK 0001570392 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 410 F2 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.875 to $87.80, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 20:20 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 6,552 | $86.25 | $565,128.35 |
DisclosureSEC source: 0001209191-20-045100 · doc4.xml · nonDerivative · entry 2 TOMSICEK MICHAEL JOHN · CIK 0001570392 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,858 F2 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.78 to $86.77, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 20:20 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 12,000 | $17.75 | $213,000.00 |
DisclosureSEC source: 0001209191-20-045100 · doc4.xml · nonDerivative · entry 1 TOMSICEK MICHAEL JOHN · CIK 0001570392 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,410 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 410 shares acquired under the CRISPR Therapeutics AG 2016 Employee Stock Purchase Plan. Read SEC document |
| June 05, 2020 Filed Jun 8, 2020 23:08 UTC | Milestone Pharmaceuticals Inc. MIST · Entity 6561 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $3.74 | $0.00 |
DisclosureSEC source: 0001209191-20-035119 · doc4.xml · derivative · entry 1 TOMSICEK MICHAEL JOHN · CIK 0001570392 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Shares · 15,000 shares Expires 2030-06-05 F1 · derivative.exercise_date: The shares subject to this option shall vest in equal monthly installments over the 12 months commencing July 5, 2020, provided that the shares subject to this option shall vest in full on the date of Issuer's 2021 annual meeting of shareholders, subject to recipient continuing to provide service to the Issuer through such vesting date. Read SEC document |
| March 10, 2020 Filed Mar 12, 2020 20:30 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantRestricted Stock Units · Derivative | 8,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-018513 · doc4.xml · derivative · entry 2 TOMSICEK MICHAEL JOHN · CIK 0001570392 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,500 Underlying: Common Shares · 8,500 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F3 · derivative.exercise_date: This restricted stock unit award was granted on March 10, 2020 with respect to 8,500 Common Shares, with (i) one third of the shares vesting on March 10, 2021, (ii) one third of the shares shares vesting on March 10, 2022, and (iii) one third of the shares vesting on March 10, 2023. F3 · derivative.expiration_date: This restricted stock unit award was granted on March 10, 2020 with respect to 8,500 Common Shares, with (i) one third of the shares vesting on March 10, 2021, (ii) one third of the shares shares vesting on March 10, 2022, and (iii) one third of the shares vesting on March 10, 2023. Read SEC document |
| March 10, 2020 Filed Mar 12, 2020 20:30 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $44.67 | $0.00 |
DisclosureSEC source: 0001209191-20-018513 · doc4.xml · derivative · entry 1 TOMSICEK MICHAEL JOHN · CIK 0001570392 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Shares · 35,000 shares Expires 2030-03-10 F1 · derivative.exercise_date: This option was granted on March 10, 2020 with respect to 35,000 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of April 10, 2020. Read SEC document |
| December 03, 2019 Filed Dec 5, 2019 21:05 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantRestricted Stock Units · Derivative | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-059280 · doc4.xml · derivative · entry 1 TOMSICEK MICHAEL JOHN · CIK 0001570392 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Shares · 20,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F2 · derivative.exercise_date: The restricted stock units shall vest as follows: two-thirds of the grant shall vest on December 3, 2021 and the remaining one-third shall vest on December 3, 2022. F2 · derivative.expiration_date: The restricted stock units shall vest as follows: two-thirds of the grant shall vest on December 3, 2021 and the remaining one-third shall vest on December 3, 2022. Read SEC document |
| March 05, 2019 Filed Mar 7, 2019 21:14 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $40.87 | $0.00 |
DisclosureSEC source: 0000899243-19-006653 · doc4.xml · derivative · entry 1 TOMSICEK MICHAEL JOHN · CIK 0001570392 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Shares · 75,000 shares Expires 2029-03-05 F1 · derivative.exercise_date: This option was granted on March 5, 2019 with respect to 75,000 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of April 5, 2019. Read SEC document |
| June 15, 2018 Filed Jun 16, 2018 01:37 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantStock Option (Right to Buy) · Derivative | 20,760 | $0.00 Strike: $59.31 | $0.00 |
DisclosureSEC source: 0000899243-18-016872 · doc4.xml · derivative · entry 1 TOMSICEK MICHAEL JOHN · CIK 0001570392 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,760 Underlying: Common Shares · 20,760 shares Expires 2028-06-15 F1 · derivative.exercise_date: This option was granted on June 15, 2018 with respect to 20,760 Common Shares with 100% of the shares vesting in 48 equal monthly installments. Read SEC document |
| March 07, 2018 Filed Mar 9, 2018 21:50 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $51.49 | $0.00 |
DisclosureSEC source: 0000899243-18-006954 · doc4.xml · derivative · entry 1 TOMSICEK MICHAEL JOHN · CIK 0001570392 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Shares · 25,000 shares Expires 2028-03-07 F1 · derivative.exercise_date: This option was granted on March 7, 2018 and shall vest in 48 equal monthly installments. Read SEC document |
| November 13, 2017 Filed Nov 14, 2017 22:19 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantStock Option (Right to Buy) · Derivative | 180,000 | $0.00 Strike: $17.75 | $0.00 |
DisclosureSEC source: 0000899243-17-026210 · doc4.xml · derivative · entry 1 TOMSICEK MICHAEL JOHN · CIK 0001570392 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,000 Underlying: Common Shares · 180,000 shares Expires 2027-11-21 F1 · derivative.exercise_date: This option was granted on November 13, 2017, 25% of the shares shall vest on November 13, 2018 and the remaining shares shall vest in 36 equal monthly installments on the first day of each succeeding calendar month. Read SEC document |
| November 13, 2017 Filed Aug 5, 2020 20:20 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,000 | $0.00 Strike: $17.75 | $0.00 |
DisclosureSEC source: 0001209191-20-045100 · doc4.xml · derivative · entry 4 TOMSICEK MICHAEL JOHN · CIK 0001570392 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,000 Underlying: Common Shares · 12,000 shares Expires 2027-11-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This option was granted on November 13, 2017, 25% of the shares vested on November 13, 2018 and the remaining shares vest in 36 equal monthly installments on the first day of each succeeding calendar month. Read SEC document |
| July 15, 2017 Filed Jul 18, 2017 16:23 UTC | ABIOMED INC ABMD · Entity 121309 | Tax withholdingCommon Stock, $.01 par value | 3,925 | $145.07 | $569,399.75 |
DisclosureSEC source: 0001179110-17-010419 · edgar.xml · nonDerivative · entry 1 TOMSICEK MICHAEL JOHN · CIK 0001570392 · Vice President, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,081 F5 · kind: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with vesting of awards of restricted stock units. F5 · shares: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with vesting of awards of restricted stock units. Read SEC document |
| May 24, 2017 Filed May 26, 2017 16:08 UTC | ABIOMED INC ABMD · Entity 121309 | Tax withholdingCommon Stock, $.01 par value | 1,567 | $134.74 | $211,137.58 |
DisclosureSEC source: 0001179110-17-008077 · edgar.xml · nonDerivative · entry 1 TOMSICEK MICHAEL JOHN · CIK 0001570392 · Vice President, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,931 F5 · kind: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with vesting of awards of restricted stock units. F5 · shares: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with vesting of awards of restricted stock units. Read SEC document |
| May 15, 2017 Filed May 17, 2017 16:50 UTC | ABIOMED INC ABMD · Entity 121309 | GrantStock option (right to buy) · Derivative | 6,000 | $0.00 Strike: $134.51 | $0.00 |
DisclosureSEC source: 0001179110-17-007419 · edgar.xml · derivative · entry 5 TOMSICEK MICHAEL JOHN · CIK 0001570392 · Vice President, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2027-05-15 F3 · security: Grant to reporting person of option to buy the number of shares of Common Stock set forth in Table II, Column 7, under the ABIOMED, Inc. 2015 Omnibus Incentive Plan. F4 · derivative.exercise_date: These options become exercisable in annual 33-1/3% increments, commencing on the date shown in Table II, Column 6. Read SEC document |
| May 15, 2017 Filed May 17, 2017 16:50 UTC | ABIOMED INC ABMD · Entity 121309 | GrantCommon Stock, $.01 par value | 1,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-007419 · edgar.xml · nonDerivative · entry 2 TOMSICEK MICHAEL JOHN · CIK 0001570392 · Vice President, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,498 F6 · kind: Consists of restricted stock units granted to the reporting person. One third of the restricted stock units will vest and the underlying shares will be issued to the reporting person on each of May 15, 2018, May 15, 2019 and May 15, 2020, so long as the reporting person continues to be employed by the issuer on the vesting dates. F6 · shares: Consists of restricted stock units granted to the reporting person. One third of the restricted stock units will vest and the underlying shares will be issued to the reporting person on each of May 15, 2018, May 15, 2019 and May 15, 2020, so long as the reporting person continues to be employed by the issuer on the vesting dates. Read SEC document |
| May 15, 2017 Filed May 17, 2017 16:50 UTC | ABIOMED INC ABMD · Entity 121309 | GrantCommon Stock, $.01 par value | 8,198 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-007419 · edgar.xml · nonDerivative · entry 1 TOMSICEK MICHAEL JOHN · CIK 0001570392 · Vice President, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,998 F5 · kind: Represents shares of common stock underlying performance-based awards of restricted stock units granted to this reporting person on May 24, 2016. One third of these restricted stock units will vest on May 24, 2017 (into an equal number of shares of common stock) based on the issuer's achievement of a certain performance milestone and upon the first anniversary of the date of the grant with the remaining vesting on the second and third anniversaries of the date of grant as long as the reporting person continues to be employed by the issuer on the vesting dates. F5 · shares: Represents shares of common stock underlying performance-based awards of restricted stock units granted to this reporting person on May 24, 2016. One third of these restricted stock units will vest on May 24, 2017 (into an equal number of shares of common stock) based on the issuer's achievement of a certain performance milestone and upon the first anniversary of the date of the grant with the remaining vesting on the second and third anniversaries of the date of grant as long as the reporting person continues to be employed by the issuer on the vesting dates. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.